Türkiye's Mobility Super App Investor Presentation February 2026 NYSE American: MRT Car-hailing | Motorcycle-hailing | Taxi-hailing | E-bike CAR | E-m-HAILING MOTORCYCLE oped | E-scooter | Motorcycle -HAILING TAXI -deliveries -HAILING E | Car-deliveries -BIKE E-MOPED E-SCOOTER Disclaimers Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securi ...

Core Insights - Monte Rosa Therapeutics announced positive interim data from the Phase 1 clinical study of MRT-8102, a NEK7-directed molecular glue degrader aimed at treating inflammatory conditions linked to the NLRP3 inflammasome, IL-1, and IL-6 [2][3] Study Results - MRT-8102 demonstrated an 85% reduction in C-reactive protein (CRP) levels after four weeks of treatment, with 94% of participants achieving CRP values below 2 mg/L, indicating a lower cardiovascular disease (CVD) risk [1][3][8] - The study included single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, showing deep and sustained NEK7 degradation across doses from 5 mg to 400 mg [1][3] - A favorable safety profile was observed, with mild to moderate adverse events and no increased infection risk reported [1][7] Future Development Plans - The ongoing GFORCE-1 study of MRT-8102 in subjects with elevated CVD risk is being expanded to include multiple dose levels, with results anticipated in the second half of 2026 [1][5] - A Phase 2 study (GFORCE-2) for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) is planned to be initiated in 2026 [1][5] - Additional indications for MRT-8102 are being evaluated, including metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis [3][5] Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases, leveraging its QuEEN™ discovery engine [9]

Core Insights - Marti Technologies, Inc. has surpassed its targets for ride-hailing service, achieving 3.38 million riders and 450 thousand registered drivers by December 31, 2025, exceeding the targets of 3.30 million riders and 450 thousand drivers [1] Group 1: Company Performance - The number of ride-hailing riders increased by 34% from August 12, 2025, to December 31, 2025 [1]

Core Viewpoint - Marti Technologies, Inc. expects to exceed its 2025 guidance and has set strong guidance for 2026, anticipating $70 million in revenue and positive adjusted EBITDA, representing over 2x year-over-year revenue growth [1][4]. Financial Outlook - For 2026, Marti projects revenue of $70 million, an increase of $36 million from the 2025 guidance of $34 million [4]. - The company anticipates achieving positive adjusted EBITDA of $1 million in 2026, a turnaround from the projected $(17) million in 2025, reflecting an improvement of $18 million [4]. Growth Drivers - Key factors driving the anticipated revenue growth and positive adjusted EBITDA include: 1. Increased ride-hailing trip volumes leading to operating leverage 2. Improved unit economics in monetized markets 3. Scaling of delivery services [2][9] - The company is focused on expanding its ride-hailing services across Türkiye, targeting an under-developed transportation and last-mile market [3]. Company Overview - Founded in 2018, Marti is Türkiye's leading mobility app, offering a range of transportation services including ride-hailing, delivery services, and a fleet of rental e-mopeds, e-bikes, and e-scooters [10].

Core Insights - Monte Rosa Therapeutics is advancing MRT-8102, a first-in-class NEK7-directed molecular glue degrader (MGD) aimed at treating cardiovascular and cardiometabolic diseases driven by the NLRP3 inflammasome [1][2][4] Group 1: MRT-8102 Overview - MRT-8102 is designed to selectively degrade NEK7, which is essential for NLRP3 inflammasome assembly and activation, thereby inhibiting inflammatory cytokine release [4][5] - The investigational drug has shown potent inhibition of pyroptotic cell death and cytokine release in preclinical studies, indicating its potential effectiveness in treating conditions like pericarditis and atherosclerosis [2][4] Group 2: Clinical Development - A Phase 1 study of MRT-8102 is currently enrolling participants, with initial data expected to be presented in the first half of 2026 [1][2] - The drug has demonstrated a significant safety margin in toxicology studies, with over a 200-fold exposure margin compared to projected human efficacious doses [5] Group 3: Scientific Presentation - Preclinical data on MRT-8102 will be presented at the American Heart Association's Scientific Sessions 2025, highlighting its unique mechanism of action in modulating the NLRP3 inflammasome [1][2] Group 4: Company Background - Monte Rosa Therapeutics focuses on developing highly selective MGD medicines for serious diseases, utilizing a proprietary discovery engine that combines AI-guided chemistry and structural biology [6]

Core Insights - Marti Technologies, Inc. has launched its ride-hailing service in 10 additional cities across Türkiye, marking the company's largest single wave of expansion to date [1] - With this rollout, Marti's ride-hailing operations now cover a total of 20 markets across Türkiye [1] - This expansion follows a successful summer rollout into six major metropolitan areas, including Bursa [1]

Core Insights - Marti Technologies, Inc. has announced the expansion of its service offerings to include same-hour package deliveries, enhancing its position as Türkiye's leading mobility super app [1] - The new package delivery services will utilize the existing network of 382,000 registered motorcycle and car drivers, along with over 6.4 million unique users of its super app [1]

Core Viewpoint - Marti Technologies, Inc. has announced an extension of its share repurchase program, allowing the company to buy back up to $2.5 million of its Class A ordinary shares until April 9, 2026 [1]. Summary by Relevant Sections - **Share Repurchase Program** - The Board of Directors has authorized a six-month extension to the existing share repurchase program [1]. - The total amount allocated for the repurchase is $2.5 million [1]. - The program was originally initiated on January [1].

Core Insights - Marti Technologies, Inc. has been added to the S&P Global Broad Market Index, effective September 22, 2025, marking a significant milestone for the company [1][2]. Company Overview - Founded in 2018, Marti is Türkiye's leading mobility app, providing a range of transportation services including ride-hailing, e-mopeds, e-bikes, and e-scooters, all supported by proprietary software and IoT infrastructure [3]. Business Growth - The company has experienced rapid growth in its ride-hailing service, achieving 2.28 million unique riders, a 107% year-over-year increase, and 327 thousand registered drivers, a 92% increase [6]. - As of August 12, 2025, Marti's ride-hailing service reached 2.52 million riders and 357 thousand registered drivers, surpassing its targets for September 30, 2025, by achieving these numbers a month and a half early [9]. Market Position - Marti's inclusion in the S&P Global BMI will enhance its visibility among index-tracking and new investors, aiding in the expansion of its ride-hailing operations to capture long-term mobility market opportunities in Türkiye [2]. - The S&P Global BMI encompasses over 14,000 companies across developed and emerging markets, employing a transparent methodology [2].

Core Insights - Marti Technologies, Inc. (MRT) is a prominent player in Türkiye's mobility sector, particularly known for its comprehensive ride-hailing super app [1] - The company reported a significant increase in ride-hailing riders, reaching 2.28 million, which is a 107% rise year-over-year [1][5] - MRT's earnings report showed an EPS of -0.31, aligning with estimates, while revenue was $14.33 million, slightly below the expected $14.43 million [2][5] Financial Metrics - MRT has a price-to-sales ratio of 9.62, indicating a high market valuation relative to its sales [3][5] - The enterprise value to sales ratio is 13.37, suggesting a substantial valuation when factoring in debt and cash [3] - The company has a negative price-to-earnings ratio of -1.87 and an earnings yield of -53.39%, reflecting ongoing financial difficulties [3] - MRT's enterprise value to operating cash flow ratio is -9.95, highlighting cash flow challenges [4] - The debt-to-equity ratio of -1.22 indicates that MRT has more liabilities than equity [4] - Despite financial hurdles, MRT maintains a current ratio of 1.69, suggesting adequate current assets to cover short-term liabilities [4]